Prostate Cancer and Prostatic Diseases

Papers
(The H4-Index of Prostate Cancer and Prostatic Diseases is 27. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-10-01 to 2025-10-01.)
ArticleCitations
The imperative for clinical trial diversity: Perspectives in the context of prostate-specific membrane antigen-targeted imaging78
Best of 2022 in prostate cancer and prostatic diseases72
A randomized controlled trial evaluating low-intensity shockwave therapy for treatment of persistent storage symptoms following transurethral surgery for benign prostatic obstruction70
Will generalist medical artificial intelligence be the future path for health-related natural language processing models?60
Reply to RE: Should LHRH therapy be continued in patients receiving Abiraterone Acetate?55
Integrating clinical and public health perspectives on statin use and prostate cancer risk: addressing key limitations and future directions51
Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or andro47
Hypofractionated radiotherapy in elderly patients (≥75 years) affected by localized prostate cancer: a multicenter retrospective analysis from the IPOPROMISE study46
Perioperative outcomes of HoLEP, ThuLEP, and TURP in patients with prostate cancer: results from the GRAND study45
More evidence that physical activity is beneficial for prostate cancer41
Prognostic value of a baseline prognostic nutritional index for patients with prostate cancer: a systematic review and meta-analysis34
New BPH therapy classification: what really FITs?34
Contemporary trends in the surgical management of urinary incontinence after radical prostatectomy in the United States34
Functional outcomes and safety of focal therapy for prostate cancer: a systematic review on results and patient-reported outcome measures (PROMs)33
Concerns regarding prostate cancer screening guidelines in minority populations32
Social determinants of health: does socioeconomic status affect access to staging imaging for men with prostate cancer32
Germline alterations among Hispanic men with prostate cancer32
Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer31
Sexual outcomes in men who have sex with men who underwent radical prostatectomy31
The promising role of new molecular biomarkers in prostate cancer: from coding and non-coding genes to artificial intelligence approaches30
Perceived patient burden and acceptability of MRI in comparison to PSA and ultrasound: results from the IP1-PROSTAGRAM study29
Effectiveness and durability of benefit of mTOR inhibitors in a real-world cohort of patients with metastatic prostate cancer and PI3K pathway alterations29
Correction: Application of next-generation imaging in biochemically recurrent prostate cancer28
TRexit is going one step further28
Concurrent prognostic utility of lymph node count and lymph node density for men with pathological node-positive prostate cancer28
A systematic review and meta-analysis to evaluate the diagnostic accuracy of PSMA PET/CT in the initial staging of prostate cancer27
Refining clinically relevant cut-offs of prostate specific antigen density for risk stratification in patients with PI-RADS 3 lesions27
0.11787605285645